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Optimizing Surveillance and Re-intervention Strategy Following
Elective Endovascular Repair of Abdominal Aortic Aneurysms
Lois G. Kim, PhD,Y Michael J. Sweeting, PhD,y David Epstein, PhD,z Maarit Venermo, MD,§
Fiona E. V. Rohlffs, MD,jj and Roger M. Greenhalgh, MD
Background: EVAR for abdominal aortic aneurysm has an initial survival
advantage over OR, but more frequent complications increase costs and long-
term aneurysm-related mortality. Randomized controlled trials of EVAR versus
OR have shown EVAR is not cost-effective over a patient’s lifetime. However, in
the EVAR-1 trial, postoperative surveillance may have been sub-optimal, as the
importance of sac growth as a predictor of graft failure was overlooked.
Methods: Real-world data informed a discrete event simulation model of
postoperative outcomes following EVAR. Outcomes observed EVAR-1 were
compared with those from 5 alternative postoperative surveillance and re-
intervention strategies. Key events, quality-adjusted life years and costs were
predicted. The impact of using complication and rupture rates from more
recent devices, imaging and re-intervention methods was also explored.
Results: Compared with observed EVAR-1 outcomes, modeling full adher-
ence to the EVAR-1 scan protocol reduced abdominal aortic aneurysm (AAA)
deaths by 3% and increased elective re-interventions by 44%. European
Society re-intervention guidelines provided the most clinically effective
strategy, with an 8% reduction in AAA deaths, but a 52% increase in elective
re-interventions. The cheapest and most cost-effective strategy used lifetime
annual ultrasound in primary care with confirmatory computed tomography if
necessary, and reduced AAA-related deaths by 5%. Using contemporary rates
for complications and rupture did not alter these conclusions.
Conclusions: All alternative strategies improved clinical benefits compared
with the EVAR-1 trial. Further work is needed regarding the cost and accuracy
of primary care ultrasound, and the potential impact of these strategies in the
comparison with OR.
Keywords: abdominal aortic aneurysms, discrete event simulation, economic
evaluation, endovascular aneurysm repair, surveillance
(Ann Surg 2019;xx:xxx–xxx)
T he endovascular aneurysm repair (EVAR) stent-graft has becomethe treatment of choice for elective repair of abdominal aortic
aneurysm. Numerous studies have demonstrated an initial survival
advantage over open repair (OR), less time in operating theatre, less use
of intensive care and lower overall length of stay in hospital.1–6
Nevertheless, EVAR is also associated in these trials with increased
late aneurysm-related mortality.6 Complications may lead to aneurysm
sac pressurization, growth and eventually rupture.7 Hence EVAR
requires more vigilant surveillance and more late re-interventions than
OR.8 As a result, EVAR has not been shown to be cost-effective over
the patient’s lifetime at conventional thresholds used in the UK.9,6
Health economic assessment of EVAR in the UK has largely
been based on long-term follow-up data from the EVAR-1 trial.6,10,11
However, it has been hypothesized that postoperative surveillance in
this trial was sub-optimal, and that a more modern surveillance
schedule might have produced a more favorable result.6 Clearly, as
the trial cannot be re-run, this theory is impossible to confirm or
refute definitively. Nevertheless, earlier detection of complications,
via a computed tomography (CT) or ultrasound (US) scan, and
appropriate corrective surgery may have prevented some ruptures.
The recommended surveillance protocol for the EVAR-1 trial was
contrast-enhanced CT at 1, 6, and 12 and yearly thereafter.12 How-
ever, this protocol was not rigorously followed,6 in part reflecting the
diversity of clinical practice at the time.13,14 The way such compli-
cations are monitored and treated has since changed radically. It is
possible some patients may have been overtreated, whereas others
who should have received re-intervention were left untreated, with
associated possible adverse consequences. Various proposals have
been made for risk-stratified surveillance strategies based on pres-
ence of early endoleak or poor component overlap.15–17 European
Society guidelines for post-EVAR follow-up have also recommended
duplex US in low-risk patients, which may lessen the cumulative
radiation dose and overall costs.16 A study in the USA revealed that a
third of the total costs of EVAR during the first 5-years was from
radiologic studies.8 However, the impact of these recommendations
on the cost-effectiveness of EVAR has not been formally assessed.
Furthermore, the rate of sac growth is an important predictor of graft
failure and rupture18 and is likely to have a proximal cause in an
underlying endoleak complication.7 Grootes et al18 found that at
2 years post-repair, positive aneurysm growth rate (>0 mm/yr)
preceded 85% of subsequent ruptures or rupture-preventing re-
interventions in the next 2 years, and 44% of patients without rupture
or rupture-preventing re-interventions had no preceding sac growth.
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The objective of this work was to evaluate the effectiveness
and cost-effectiveness of different surveillance and re-intervention
strategies using data from both the EVAR-1 and EVAR-2 trials and a
contemporary cohort from Helsinki University Hospital (HUH) in
Finland. A model was constructed to investigate the clinical and cost
implications of different protocols under different generations of
EVAR devices, without having to conduct another costly and long-
term randomized trial.
METHODS
A discrete event simulation model was developed in R to
contrast different potential post-EVAR surveillance strategies in
terms of key events, life-years and costs. The reference case assessed
the long-term cost-effectiveness of the postoperative surveillance and
re-intervention strategy observed in the EVAR-11 trial, since this
most closely approximates real-life practice. We additionally
assessed 5 further strategies, including the official protocol of the
EVAR-1 trial.
Model Structure
Key events included in the model were abdominal aortic
aneurysm (AAA)-related complications, ruptures, re-interventions,
and deaths. Complications were divided into: (1) a composite
outcome comprising any of: kinking, migration, endoleak type I,
endoleak type III (hereafter referred to as ‘‘restricted cluster’’
complications), (2) endoleak type II, (3) preoperative sac growth:
10 mm change in sac diameter from preoperative diameter, (4)
large sac growth: 5 mm per annum pro rata expansion based on
scans6 months apart, and (5) small sac growth:0 mm and<5 mm
per annum pro rata expansion, based on scans 6 months apart.
These categories reflect complications that are important predictors
of postoperative events (including other complication types) and/or
are of interest as indicators of future surveillance or re-intervention
strategies. The use of the ‘‘restricted cluster’’ of complications
enables endoleak type II to be tracked separately from sac growth,
and so differs from the ‘‘cluster’’ previously described6 [which
comprises (1) together with (2) and (4) in combination]. This is
important here because some policies of interest seek to make
management decisions based on sac growth alone (ie, without
reference to endoleak type II). Furthermore, because endoleak type
II alone may not be considered severe enough to warrant interven-
tion, we did not include it in the restricted cluster definition. This,
therefore, enables modeling of sac growth in conjunction with
endoleak type II and sac growth alone.
Fig. 1 shows the model structure. Decision events relate to
scans (timing and modality, CT/US) and elective re-interventions.
Stochastic events were complications, rupture, emergency re-inter-
vention, AAA-related death, or other causes of death. Modeling of
complications was restricted to30 days postintervention to exclude
in-hospital complications in same admission as the index interven-
tion. In the model, complications that occur were only detected at the
next scan, with a given sensitivity. However, patients become at risk
FIGURE 1. Structure of the discrete event simulation model. Circles ¼ uncosted events; rectangles ¼ costed events. Green arrows
indicate transitions from any of the complication states contained in the green box. Late operative mortality (>30 d) represents
deaths coded as AAA-procedure-related mortality occurring >30 d after last re-intervention, without rupture.
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of rupture from the time the complication occurs. Therefore, long
surveillance intervals increase the risk that an undetected complica-
tion will lead to rupture.
Alternative Policies
Six surveillance/re-intervention protocols were modeled.
Strategy A models the EVAR Trials under imperfect adherence to
surveillance and re-intervention protocols. This strategy serves as a
reference for comparison with alternative strategies. In this model,
the empirical distribution of time to next CT scan, stratified by
number of previous scans, was used to generate scan times. Similarly,
the time to re-intervention of a detected complication was modeled
using observed times in the EVAR trials.6 This reflects the lack of
formal re-intervention policy in the trials, meaning this decision
varied according to clinician discretion and local practice. Numbers
and timings of key events predicted from Strategy A were compared
to those observed in the trials (internal validation).
Strategy B models surveillance according to the EVAR trials
stated protocol (CT scan at 1 m, 6 m, 12 m and annually thereafter)19
but still with no formal re-intervention policy. Strategy C uses the
trial scan protocol together with the European Society for Vascular
Surgery 2011 re-intervention guidelines16 (elective re-intervention if
‘‘restricted cluster’’ or preoperative sac). Strategy D uses the Euro-
pean Society for Vascular Surgery scan protocol (6-month scan
omitted in patients without a previous complication/re-intervention;
US in low-risk patients after 12 months) and re-intervention proto-
col.16 Strategy E has no long-term follow-up: annual US surveillance
to 5 years (with immediate CT confirmation for cluster and preoper-
ative sac growth detected by US) and no further scans thereafter. This
is based on the premise that most post-EVAR complications occur
early, with much lower risk of rupture thereafter. Strategy F considers
a novel scan protocol using a 3-month (rather than 1-month) CT scan.
There is subsequently a 2-stage surveillance process, with (1)
surveillance scans at 12 months and annually using portable US
in a primary care setting and (2) immediate CT to look for restricted
cluster complications where the US scan finds positive sac growth
(>0 mm/yr pro-rata). All subsequent scans for these individuals are
then via CT until re-intervention. Re-intervention is undertaken if
type II endoleak with large sac growth (>5 mm/annum) or any
restricted cluster complication is found at any CT scan.
Rate Estimation
Model transition rates and probabilities (Fig. 1) were esti-
mated using individual patient data from (i) the EVAR-11,10 and
EVAR-22,20 trials combined, accounting for case-mix (‘‘base-case’’)
and (ii) a contemporary cohort of patients recruited from 2000 to
2015 in HUH, Finland18 (sensitivity analysis).
For the base-case, we included all patients who had an elective
EVAR operation (in either trial arm), excluding those who converted to
OR during the primary operation. The HUH cohort was used only to
update the rates of complications (including rupture), receipt of
intervention after rupture and postoperative mortality, to reflect how
the proposed strategies might perform in the same EVAR-1 patient
cohort if they were treated with later generation endovascular devices,
improved imaging, and re-intervention techniques. Time to each
complication type, rupture, and non-AAA death was modeled, with
adjustment for age, sex, and previous complications when these effects
were statistically significant (P< 0.05). In the estimation of empirical
time to re-intervention (Strategies A and B only), number of previous
re-interventions were adjusted for as an a priori factor for face validity.
In the EVAR trials, complications occurred at a high rate in the
3 months after intervention (28 restricted cluster complications and
32 type II endoleaks per 100 person-years). After 6 months rates for
both reduced to 3 events per 100 person-years. In HUH, rates in the
first 3 months were 30 and 60 per 100 person-years for restricted
cluster complications and type II endoleaks, respectively, and 3–5
events per 100 person-years after 6 months. In the EVAR trials, rates
for small and large sac expansion in the first year were around 5 per
100 person-years, but the rate of small sac expansion increased in
subsequent years to 11 per 100 person-years- (Supplement Table 8,
http://links.lww.com/SLA/B798). Rates of large and small sac
expansion were generally lower in HUH, with around 4 per 100
person-years after 2 years. Hazard ratios for factors affecting these
rates (including prior occurrence of other complications) are given in
TABLE 1. Total Numbers of Events at 15 yr, for a Cohort of N ¼ 848 (EVAR-1 and EVAR-2 Patients) Observed in the Trial Data
and Predicted by Strategy A (Internal Validation)
Event EVAR Observed Strategy A % Change from Observed
Modeled Scan Policy NA Empirical
Modeled Re-intervention Policy NA Empirical
CT scans 4274 4732 11%
US scans NA NA NA
Restricted cluster complications 201 186 7%
Type II endoleaks 195 194 1%
Small sac growth 339 368 9%
Large sac growth 205 209 2%
Preoperative sac growth 120 121 1%
Elective re-interventions 185 184 1%
Emergency re-interventions 11 12 9%
Ruptures 44 44 0%
AAA deaths 70 72 3%
Non-AAA deaths 609 666 9%
Mean costs £3283y £3517 7%
Mean life-years 7.476z 7.398 1%
Censoring-inflated for: elective re-interventions, complications and non-AAA deaths. Excludes events occurring post-(re)-intervention in those with 30 d postoperative mortality.
Excludes complications occurring within 30 d of an (re)intervention.
yCalculated directly from observed numbers of events and costs used as model inputs.
zKaplan-Meier restricted mean life-years (based on all-cause mortality, accounting for censoring) at 15-yr.
CT indicates computed tomography; EVAR, elective endovascular aneurysm repair; NA, not applicable; US, ultrasound.
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TABLE 2. Total Numbers of Events at Lifetime, for a Cohort of N ¼ 10,000 EVAR-1-type Patients Undergoing an Initial EVAR Procedure: Using Rates Estimated
from EVAR Trials
Event Strategy A Strategy B Strategy C Strategy D Strategy E Strategy F
Events Events % Changey Events % Changey Events % Changey Events % Changey Events % Changey
Scan policy Empirical EVAR Policy EVAR Policy ESVS Follow-up Until 5-yr Primary Care US
Re-intervention policy Empirical Empirical ESVS ESVS ESVS High Risk
CT scans 61,375 102,326 67% 102,867 68% 49,322 20% 15,002 76% 49,075 20%
US scans NA NA NA NA NA 51,510 NA 51,784 NA 53,094 NA
Restricted cluster
complications
2503 2600 4% 2695 8% 2676 7% 2535 1% 2496 0%
Type II endoleaks 2446 2567 5% 2472 1% 2475 1% 2361 3% 2371 3%
Small sac growth 4948 5095 3% 4919 1% 4918 1% 4774 4% 5111 3%
Large sac growth 2715 2832 4% 2785 3% 2786 3% 2682 1% 2714 0%
Preoperative sac growth 1514 1554 3% 1687 11% 1692 12% 1611 6% 1448 4%
Elective re-interventions 2608 3764 44% 3955 52% 3883 49% 2625 1% 2175 17%
Emergency re-interventions 169 153 10% 132 22% 135 20% 160 5% 155 8%
Ruptures 617 553 10% 487 21% 497 19% 579 6% 565 8%
AAA deaths 963 930 3% 889 8% 897 7% 935 3% 915 5%
Non-AAA deaths 9037 9070 0% 9111 1% 9103 1% 9065 0% 9085 1%
NNT to prevent 1 AAA
deathy
NA 304 134 150 350 205
Mean costs, discountedz (%





































Figures in Strategies B-F are numbers of underlying complications (rather than detected complications).
Restricted cluster complication or type II endoleak plus large sac growth.
yCompared to Strategy A.
zMeans with uncertainty intervals derived from 1000 probabilistic sensitivity analysis iterations.
§Calculated at a willingness to pay of £20,000 per QALY.
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Supplement Tables 3, http://links.lww.com/SLA/B798 and 4, http://
links.lww.com/SLA/B798. The occurrence of small or large sac
expansion increased the restricted cluster complication (ie, migra-
tion, kinking, type I or III endoleak) rate by approximately 60% in the
EVAR trials. In the EVAR trials, 28% of those rupturing had an
emergency re-intervention; 30-day postoperative mortality (AAA-
related) was 2.6% after the initial EVAR operation, 1.7% after
elective re-intervention, and 27% after emergency re-intervention
(Supplement Table 4, http://links.lww.com/SLA/B798). In HUH, 30-
day postoperative mortality was much lower at 0.3% after the initial
operation and 0.9% after elective re-intervention.
Costs and Health-related Quality of Life (HRQOL)
The perspective is that of the UK National Health Service, the
price year is 2015/2016, and the discount rate is 3.5% per year.21
Costs were ascribed to scans, emergency, and elective re-interven-
tions.22 The cost of the initial aneurysm repair was not included as the
study is concerned only with postintervention follow-up. Mean life-
years were calculated as the meantime to all-cause mortality. Qual-
ity-adjusted life-years (QALYs) accounted for reduced HRQOL after
elective and emergency re-interventions. Costs, HRQOL weights
(utilities) and scan sensitivity to detect complications are given in the
Supplement, http://links.lww.com/SLA/B798.
Model Implementation and Validation
The model was run for 500,000 iterations (see Supplement,
http://links.lww.com/SLA/B798), where each iteration represents
a hypothetical individual drawn randomly from the required
population. For the Strategy A validation, draws are made from
a population with the same age and sex distributions as the
EVAR-1 and EVAR-2 trials, and run for up to 15 years to match
trial follow-up. Subsequently, for strategies A-F, draws were
made from a population with EVAR-1-like age and sex character-
istics and run until death to give a lifetime time-horizon. Event
numbers for the initial validation were scaled to the cohort size
(N ¼ 848) for comparison with observed data. For the strategy
comparisons, event numbers are scaled to a cohort of
10,000 patients.
A probabilistic sensitivity analysis was undertaken to quan-
tify uncertainty in the outcomes. One thousand Monte Carlo sim-
ulations, each with 100,000 hypothetical individuals, were
performed with regression parameters for each transition sampled
jointly from their asymptotic multivariate distributions (see Sup-
plement, http://links.lww.com/SLA/B798). The overall mean cost,
QALYs and incremental net benefit compared to Strategy A were
calculated and uncertainty summarized using the 2.5th and
97.5th percentiles.
FIGURE 2. Differences in numbers of key events for Strategies B-F compared to Strategy A, for 10,000 individuals (lifetime models
based on rates estimated from EVAR trials). EVAR indicates elective endovascular aneurysm repair.
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Sensitivity Analyses
Sensitivity analysis is used to investigate how robust model
outputs are (mean total cost and mean QALYs) to variation in model
inputs. The cost and sensitivity of US in primary care to detect sac
growth (Strategy F) is uncertain, as this technology has not been
implemented. The base-case assumes US detects all sac growth
events with the cost of a primary care US taken from NHS reference
costs for an in-hospital US scan (minus any outpatient costs). In
sensitivity analysis I, the base-case cost for a US scan (£58) was
doubled in a one-way sensitivity analysis. In sensitivity analysis II, it
was assumed that 40% of sac growth events go undetected via this
method. Sensitivity analysis III is a multi-way sensitivity analysis
using rates of complications and operative mortality estimated from
HUH data, and re-evaluating all 6 strategies based on these rates.
RESULTS
Model Validation
Strategy A simulates the surveillance and re-intervention rates
as seen in the EVAR 1 and 2 trials and is used to validate the discrete
FIGURE 3. Contour plots (ellipses)
with efficiency frontier (dotted
line) for lifetime results from Strat-
egies A-F, using (A) Model based
on rates estimated from EVAR tri-
als, (B) Model based on rates esti-
mated from HUH cohort. EVAR
indicates elective endovascular
aneurysm repair; HUH, Helsinki
University Hospital.
Kim et al Annals of Surgery  Volume XX, Number XX, Month 2019
6 | www.annalsofsurgery.com  2019 The Author(s). Published by Wolters Kluwer Health, Inc.
CE: D.C.; ANNSURG-D-19-01630; Total nos of Pages: 10;
ANNSURG-D-19-01630
event simulation (see Supplement, http://links.lww.com/SLA/B798).
Predicted numbers of events at 15 years were generally well-cali-
brated (within10%) with the observed events in the trials (Table 1).
Model Outputs
All strategies showed a reduction in ruptures compared to
Strategy Awith the largest reductions in Strategies C and D (Table 2).
Strategies B, C, and D also showed large increases in elective re-
interventions; in the case of Strategies B and C because there were
more CT scans, and in the case of Strategies C and D because these
models also assumed adherence to a strict re-intervention policy.
Fig. 2 shows the differences in events over time for each lifetime
model compared to Strategy A.
Because Strategy F only sends patients with US-detected sac
growth (and not those with restricted cluster events alone) for CT and
possible re-intervention, this policy has considerably fewer elective
re-interventions than other strategies. There are fewer ruptures than
Strategy A, though ruptures are higher than the more intense
surveillance strategies (Strategies C and D). Strategies C and D
are the most clinically effective strategies giving a 7%–8% reduction
in AAA deaths compared with Strategy A. Nevertheless, as these
patients are elderly, this does not translate to substantially increased
life-years. Strategy F shows a 13% reduction in costs, which arises
because US scans in primary care are substantially cheaper than in
hospital and because there are considerably fewer elective re-inter-
ventions. Overall, compared to Model A, the number needed to treat
to prevent 1 AAA death is lowest in Strategies C and D, highlighting
the clinical effectiveness of these strategies (Table 2).
In the base case model, Strategies A, B, and E would not be
cost-effective at any willingness to pay for a QALY, because they are
more expensive and less effective than other options. (Fig. 3A).
Strategy C offers a slightly greater QALY gain than F, but at
considerably greater cost, giving an incremental cost-effectiveness
ratio (ICER) for C versus F of over £325,000/QALY. Strategy D
would not be considered cost-effective because it has an even higher
ICER compared to Strategy F, but fewer QALYs than C. At a
willingness to pay of £20,000/QALY, after accounting for parameter
uncertainty, the likelihood that Strategy F is the most cost-effective
option is over 90%.
Sensitivity Analyses
Sensitivity analysis I examined the impact of doubling the cost
of US scan in primary care, from £58 to £116. The mean total cost per
patient increased by 9% compared to a model using £58, but strategy
F was still the most cost-effective. Sensitivity analysis II investigated
the impact of a reduction in accuracy of US in primary care to detect
sac growth from 100% to 60%. This reduced the clinical effective-
ness by 8%, but also reduced CT scans, elective re-interventions, and
costs; strategy F was still the most cost-effective (Table 3).
Modeling based on HUH event rates (sensitivity analysis III)
shows a similar pattern of results (Table 4), though the absolute
numbers of ruptures are higher (due to a higher observed rupture rate
in HUH) whilst AAA deaths are lower, due to substantially improved
postoperative mortality after elective (re)-interventions. Similarly to
the base case model, Strategies A, B, and E would not be cost-
effective at any willingness to pay for a QALY (Fig. 3B). The ICER
for C versus F using the HUH data is over £346,000/QALY; D versus
F has an even higher ICER compared to F, but fewer QALYs than C.
At a willingness to pay of £20,000/QALY, the probability that
Strategy F is the most cost-effective option remains over 90%.
TABLE 3. Sensitivity Analysis I and II Results: Total Numbers of Events at Lifetime, for a Cohort of N ¼ 10,000 EVAR-1-type
Patients Undergoing an Initial EVAR Procedure: Using Rates Estimated from EVAR Trials




Events Events % Changey Events % Changey Events % Changey
Scan Policy Empirical Primary Care US As F With Primary Care
US Cost 2
As F With Primary Care
US Sensitivity ¼ 0.6
Re-intervention Policy Empirical High Risk High Risk High Risk
CT scans 61,375 49,075 20% As strategy F 45,434 26%
US scans NA 53,094 NA 56,176 NA
Restricted cluster complications 2503 2496 0% 2481 1%
Type II endoleaks 2446 2371 3% 2368 3%
Small sac growth 4948 5111 3% 5078 3%
Large sac growth 2715 2714 0% 2702 0%
Preoperative sac growth 1514 1448 4% 1450 4%
Elective re-interventions 2608 2175 17% 2081 20%
Emergency re-interventions 169 155 8% 162 4%
Ruptures 617 565 8% 583 6%
AAA deaths 963 915 5% 923 4%
Non-AAA deaths 9037 9085 1% 9077 0%
NNT to prevent 1 AAA deathy NA 205 As strategy F 246
Mean costs, discountedz £3391 £2964 13% £3223 5% £2839 16%
Mean quality-adjusted life-years
(QALYs), discountedz
5.491 5.507 0.3% 5.507 0.3% 5.505 0.3%
Incremental net benefity,z,§ NA £738 £478 £832
Figures in Strategies F are numbers of underlying complications (rather than detected complications).
Restricted cluster complication or type II endoleak plus large sac growth.
yCompared to Strategy A.
zCalculated deterministically.
§Calculated at a willingness to pay of £20,000 per QALY.
CT indicates computed tomography; EVAR, elective endovascular aneurysm repair; NNT, number needed to treat; US, ultrasound.
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TABLE 4. Sensitivity Analysis III Results: Total Numbers of Events at Lifetime, for a Cohort of N ¼ 10,000 EVAR-1-type Patients Undergoing an Initial EVAR
Procedure: Using Rates Estimated from HUH Cohort
Event Strategy A Strategy B Strategy C Strategy D Strategy E Strategy F
Events Events % Changey Events % Changey Events % Changey Events % Changey Events % Changey
Scan Policy Empirical EVAR Policy EVAR Policy EJVES Follow-up Until 5-yr Primary Care US
Re-intervention Policy Empirical Empirical EJVES EJVES EJVES High Risk
CT scans 62,892 104,436 66% 105,940 68% 61,620 2% 15,453 75% 33,750 46%
US scans NA NA NA NA NA 41,282 NA 53,962 NA 69,481 NA
Restricted cluster
complications
2796 2928 5% 2970 6% 2950 6% 2798 0% 2651 5%
Type II endoleaks 5525 5954 8% 5435 2% 5434 2% 5098 8% 5209 6%
Small sac growth 2712 2753 2% 2662 2% 2674 1% 2642 3% 2833 5%
Large sac growth 2787 2861 3% 2853 2% 2846 2% 2761 1% 2906 4%
Preoperative sac growth 1474 1543 5% 1602 9% 1593 8% 1528 4% 1356 8%
Elective re-interventions 3390 4953 46% 4033 19% 3944 16% 2658 22% 2409 29%
Emergency re-interventions 455 434 5% 397 13% 399 12% 432 5% 416 9%
Ruptures 897 866 3% 794 11% 802 11% 861 4% 839 6%
AAA deaths 694 688 1% 624 10% 634 9% 663 4% 648 7%
Non-AAA deaths 9306 9312 0.1% 9376 0.8% 9366 0.6% 9337 0.3% 9352 0.5%
NNT to prevent 1 AAA
deathy
NA 1667 143 167 323 217
Mean costs, discountedz (%





































Figures in Strategies B-F are numbers of underlying complications (rather than detected complications).
Restricted cluster complication or type II endoleak plus large sac growth.
yCompared to Strategy A.
zMeans and uncertainty intervals derived from 1000 probabilistic sensitivity analysis iterations.
§Calculated at a willingness to pay of £20,000 per QALY.
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DISCUSSION
Follow-up surveillance in the EVAR trials did not closely
follow protocol and may have been sub-optimal. Deviations from
protocol arose as postoperative care decisions were made in the
absence of evidence to inform best practice. Modeling of full
protocol adherence confirmed that this approach would have reduced
ruptures and AAA deaths; however, the results also suggest that there
would have been an associated large increase in elective re-inter-
ventions, which come at a considerable extra cost. Furthermore, all
the other strategies we considered increased mean life-years com-
pared to the observed data.
Among the 5 alternative postoperative surveillance strategies
evaluated, European Society guidelines offer the largest clinical
benefit, but the difference between strategies in terms of QALYs
is very small. A primary care US strategy provides substantial cost
savings, and therefore results in the most cost-effective approach to
post-EVAR care.
Adopting a strategy of primary care US scanning that only
measures sac growth has a number of implications. In the EVAR
trials, 62% of new restricted cluster complications (ie, kinking,
migration, endoleak type I and III) are not preceded by recorded
sac growth. Such individuals would not receive elective re-interven-
tion under this strategy until sac growth causes them to be sent for a
CT scan, where the cluster complication can be identified. Therefore
this primary care strategy may delay elective re-intervention in these
patients if sac growth is not evident. However, this also means that
elective re-intervention is restricted only to those most at risk of
future rupture, thus considerably reducing overall costs. This strategy
also reduces CT scans, further reducing costs, and is likely to be
preferred by patients, who are able to remain at or near home and to
avoid annual hospital visits.
Our modeling uses real-world data from ground-breaking
clinical trials. The data from the EVAR-1 and EVAR-2 trials covers
up to 15 years follow-up, hence life-time extrapolation for these
patients, whose average age is 75, can be considered reasonably
robust. Internal validation of the model against the observed data
performed well, giving confidence that the model provides a good
representation of the underlying system. Additionally, modeling
using contemporary data from Helsinki suggests that conclusions
regarding the optimal surveillance strategy are unchanged in patients
with current-generation endovascular devices.
Nevertheless, the study employs some assumptions, which
may be limitations. To provide the most robust estimates possible of
event rates, data from patients in both the EVAR-1 and EVAR-2 trials
were pooled (averaged), though there may be some additional frailty
for scan recall and events in the EVAR-2 patients not accounted for
by factors included in our rate modeling. A common strategy is
employed across all patients in each of the strategies; a larger dataset
may enable exploration of the possibility that a stratified approach
may further maximize clinical benefits. The study considers that
handheld portable US carried out quickly and cheaply in primary
care (without a hospital outpatient visit) can accurately identify those
most at risk of future rupture by using an indicator of any sac growth
over 0 mm/annum.23 However, US-measured sac diameters may be
subject to significant inter-observer variability,24 leading to less
accurate detection of true sac growth. Uncertainty regarding the
cost and accuracy of primary care-based US to detect sac growth was
assessed in sensitivity analyses, and did not materially affect the
results. The study also does not assume that primary care-based US
could confirm cluster complications, which would still require
hospital CT. However, these results should be treated with caution,
as such an approach requires full testing and validation of feasibility,
sensitivity, and specificity in primary care before recommendation.
This work has not included an OR policy arm. Nevertheless,
these findings have important implications relevant to the ongoing
debate regarding the cost-effectiveness of EVAR versus OR. A
previous analysis using long-term follow-up data from the EVAR-
1 trial showed small QALY gains for EVAR but significantly higher
mean lifetime costs of over £3500, with an ICER of over £200,000.6
This analysis assumed a postoperative surveillance policy similar to
Strategy A. We have shown that alternative surveillance and re-
intervention policies may increase QALYs gained. Furthermore, a
new policy using primary care US additionally reduces costs con-
siderably and can be expected to substantially improve cost-effec-
tiveness of EVAR in comparison to OR. Comprehensive comparison
of EVAR versus OR using latest devices, imaging, endovascular re-
intervention techniques and local anesthetic for shorter hospital stays
is, therefore, needed.
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